RESULT OF GENERAL MEETING AND DIRECTORS DEALING

RNS Number : 7066J
Oxford Biomedica PLC
16 June 2014
 



 

 

 

 

 

 

FOR IMMEDIATE RELEASE

16 June 2014

                                               

OXFORD BIOMEDICA PLC

RESULT OF GENERAL MEETING AND DIRECTORS DEALING

 

Oxford, UK - 16 June 2014: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its General Meeting, held today in London.

 

In accordance with Listing Rule 9.6.18, the following resolution passed at the meeting concerned special business:

 

·      Resolution 2: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of £12,832,486.16.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 134 to 136 of the prospectus dated 29 May 2014).

 

Certified copies of the document setting out the above resolutions passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

 

The results of the proxy voting in advance of the meeting are shown below.

 

 

 

Resolution

 

Votes 

For

Votes at 

Chairman's

Discretion

Votes at 

other proxy

Discretion

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result









Ordinary resolution






1

677,773,077

995,046

11,700

569,956

18,474

679,368,253

Passed









Special resolution






2

677,820,393

589,675

11,700

309,110

637,375

679,368,253

Passed









Ordinary resolution






3

313,817,070

689,296

11,700

664,606

185,581

315,368,253

Passed









 

 

In addition, following the proposed fundraising announced on 29 May 2014, the table below details the Number of Ordinary Shares now beneficially held by the Directors and their connected persons in the share capital of the Company:

 

Name of Director

Title

Number of Ordinary Shares Purchased

Number of Ordinary Shares beneficially held immediately following Admission

Percentage of issued ordinary shares beneficially held immediately following Admission

Nick Rodgers

Non-Executive Chairman

200,000

1,042,829

0.04%

John Dawson

Chief Executive Officer

500,000

2,782,829

0.11%

Peter Nolan

Senior Vice President, Commercial Development

150,000

883,313

0.04%

Tim Watts

Chief Financial Officer

1,625,000

5,307,829

0.21%

Dr. Paul Blake

Non-Executive Director

1,250,000

1,783,097

0.07%

Dr. Andrew Heath

Non-Executive Director

250,000

850,000

0.03%

Martin Diggle 1

Non-Executive Director

132,250,000

533,250,100 2

21.38% 2

 

(1)  Includes interests of Vulpes Life Sciences Fund and other parties connected to Martin Diggle

(2)  Includes the Related Party Subscription

 

-Ends-

 

For further information, please contact:

 

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

 

 

Tel: +44 (0)1865 783 000

 

 

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

Tel: +44 (0)20 3709 5700

 

Notes to editors

 

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCZMGMVMVRGDZM